Biophan Technologies Continues Rapid Expansion of Patent Portfolio; Total Portfolio Increases to 74 Patents Issued, Allowed, and/or Pending.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH) an innovator, developer, and marketer of MRI-related and other advanced biomedical technology, announced today that five new patents have issued and five patents have been allowed by the U.S. Patent and Trademark Office. Additional patents have been filed and are pending. This substantial increase in its proprietary technology base brings Biophan's total U.S. portfolio, owned, as well as exclusively licensed, to 14 issued and 6 allowed patents, in addition to 54 applications in process, for a total of 74. Foreign patents are also pending.

"In the biomedical device industry, a company's intellectual property is vital", stated Michael Weiner, CEO of Biophan. "With over twenty patents issued or allowed (meaning they will issue within several months) and 54 more in process, we are achieving our strategic goal of cornering the market with respect to MRI safety and image compatibility. As the industry transitions to this capability, and as products and technologies become market-ready, this patent portfolio will become increasingly more important."

Nanoset, LLC, an East Rochester, New York technology developer working with Biophan, recently filed multiple new patents for the use of nanomagnetic particles. These technologies can be used to reduce image artifacts on implantable and interventional medical devices and for a new class of applications to enhance the uptake, release, and monitoring of drugs in medical device coatings. Biophan holds the exclusive rights to all medical applications developed by Nanoset.

"This work by Nanoset, plus our acquisition of a majority interest in TE-Bio, which is developing our biothermal battery technology, contributed to this significant growth in our patent estate. As a result of our internal innovation and our work with affiliates, we have been able to grow our portfolio very quickly and significantly," Weiner continued. "Interest in our technology solutions and patent portfolio by major industry players is also growing."

Owner              Issued      Allowed      Pending          Total

Biophan              7            4            32              43
Nanoset              4            2            21              27
TE-Bio               1                          1               2
Johns Hopkins        1                                          1
D. Chung             1                                          1

Total               14            6            54              74

Interested parties may view selected patents from Biophan's portfolio at http://www.biophan.com/intellectual.php.

About Biophan Technologies

Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have fourteen issued U.S. patents and over sixty patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, biothermal batteries, and photonics. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of the Company's MRI technologies; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs; the acceptance by the market of the Company's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.